Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study

被引:84
作者
Shin, Ju-Young [1 ,2 ,3 ,4 ]
Roughead, Elizabeth E. [5 ]
Park, Byung-Joo [6 ]
Pratt, Nicole L. [5 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Res Inst, Ctr Clin Epidemiol, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada
[3] McGill Univ, Dept Biostat, Montreal, PQ, Canada
[4] McGill Univ, Dept Occupat Hlth, Montreal, PQ, Canada
[5] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia
[6] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea
来源
BMJ-BRITISH MEDICAL JOURNAL | 2016年 / 353卷
基金
澳大利亚国家健康与医学研究理事会;
关键词
NERVOUS-SYSTEM STIMULANTS; AMBULATORY BLOOD-PRESSURE; RISK; EVENTS; ADOLESCENTS; MEDICATIONS; DESIGNS; DRUGS; DEATH;
D O I
10.1136/bmj.i2550
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. DESIGN Self controlled case series analysis. SETTING Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. PARTICIPANTS 1224 patients aged <= 17 who had experienced an incident cardiovascular event and had had at least one incident prescription for methylphenidate. MAIN OUTCOME MEASURES A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50). Incidence rate ratios were calculated with conditional Poisson regression and adjusted for time varying comorbidity and comedication. RESULTS Increased risk of arrhythmia was observed in all exposed time periods-that is, periods of treatment with methylphenidate-(incidence rate ratio 1.61, 95% confidence interval 1.48 to 1.74), and the risk was highest in the children who had congenital heart disease. No significant risk of myocardial infarction was observed for all exposed time periods (1.33, 0.90 to 1.98), though risk was higher in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. CONCLUSION The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly in children with mild ADHD.
引用
收藏
页数:8
相关论文
共 50 条
[31]   Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome [J].
Roche, M. ;
Mircher, C. ;
Toulas, J. ;
Prioux, E. ;
Conte, M. ;
Ravel, A. ;
Falquero, S. ;
Labidi, A. ;
Stora, S. ;
Durand, S. ;
Megarbane, A. ;
Cieuta-Walti, C. .
JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2021, 65 (08) :795-800
[32]   Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder [J].
Childress, Ann C. ;
Lloyd, Eric ;
Jacobsen, Leslie ;
Gunawardhana, Lhanoo ;
Johnson, Steven A., Jr. ;
Findling, Robert L. .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2022, 61 (12) :1423-1434
[33]   Efficacy and Safety of Methylphenidate and Atomoxetine in Medication-Naive Children with Attention-Deficit Hyperactivity Disorder in a Real-World Setting [J].
Zhang, Ying ;
Yin, Li ;
You, Cun ;
Liu, Chunxue ;
Dong, Ping ;
Xu, Xiu ;
Zhang, Kaifeng .
DRUGS IN R&D, 2024, 24 (01) :29-39
[34]   Does Methylphenidate Reduce Testosterone Levels in Humans? A Prospective Study in Children with Attention-Deficit/Hyperactivity Disorder [J].
Wang, Liang-Jen ;
Chou, Miao-Chun ;
Chou, Wen-Jiun ;
Lee, Min-Jing ;
Lin, Pao-Yen ;
Lee, Sheng-Yu ;
Lee, Yi-Hsuan .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2017, 20 (03) :219-227
[35]   Injury Prevention by Medication Among Children With Attention-Deficit/Hyperactivity Disorder A Case-Only Study [J].
Mikolajczyk, Rafael ;
Horn, Johannes ;
Schmedt, Niklas ;
Langner, Ingo ;
Lindemann, Christina ;
Garbe, Edeltraut .
JAMA PEDIATRICS, 2015, 169 (04) :391-395
[36]   Attention-deficit hyperactivity disorder comorbidity and antidepressant resistance among patients with major depression: A nationwide longitudinal study [J].
Chen, Mu -Hong ;
Pan, Tai -Long ;
Hsu, Ju-Wei ;
Huang, Kai -Lin ;
Su, Tung -Ping ;
Li, Cheng-Ta ;
Lin, Wei -Chen ;
Tsai, Shih-Jen ;
Chang, Wen -Han ;
Chen, Tzeng-Ji ;
Bai, Ya-Mei .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (11) :1760-1767
[37]   Factors associated with attention-deficit/hyperactivity disorder among Tunisian children [J].
Guedria, Asma ;
Guedria, Mohamed ;
Ben Fredj, Manel ;
Ayoub, Randaline ;
Ben Abid, Hela ;
Mhalla, Ahmed ;
Slama, Hela .
FRONTIERS IN PSYCHIATRY, 2025, 16
[38]   Executive functions among male children with attention-deficit/hyperactivity disorder [J].
Hampel, Petra ;
Petermann, Franz ;
Desman, Christiane .
KINDHEIT UND ENTWICKLUNG, 2009, 18 (03) :144-152
[39]   Treatment of Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Irritability: Results From the Multimodal Treatment Study of Children With ADHD (MTA) [J].
Fernandez de la Cruz, Lorena ;
Simonoff, Emily ;
McGough, James J. ;
Halperin, Jeffrey M. ;
Arnold, L. Eugene ;
Stringaris, Argyris .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2015, 54 (01) :62-70
[40]   Pharmacotherapy and Academic Achievement Among Children with Attention-Deficit/Hyperactivity Disorder [J].
Barnard-Brak, Lucy ;
Brak, Victor .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2011, 21 (06) :597-603